We are honored by the ongoing recognition of Forbes Magazine for the outstanding business growth that our employees have achieved as we continue to drive
superior value for our customers and our shareholders. This year Myriad moved up 33 spots in the Forbes ranking to number 16.

The ranking reflects Myriad’s outstanding business performance. In FY2014 our revenues were a record $778 million, an increase of 27 percent over the prior
year, and the Company’s five-year Compound Annual Growth Rate (CAGR) was approximately 17 percent. Importantly, we are well positioned to continue to
deliver long-term value for our shareholders and address the diagnostic needs of today’s healthcare system. We have invested $200 million in R&D since
2011, and today have an industry-leading pipeline of new molecular diagnostic and companion diagnostic tests. We’re also focused on expanding
internationally and bringing our life-saving products to more patients worldwide.

Forbes 2014 list of the 100 Best Small Companies in America recognizes remarkable sales and earnings growth among public companies with annual revenues
between $5 million and $1 billion and a stock price no lower than $5 a share. Rankings are based on earnings growth, sales growth and return on equity in
the past 12 months and over five years, and on the company’s stock performance relative to its peer group.

Read the Forbes article.

Investor Day

August 11, 2022